The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-4329
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2026
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Fedorova N.V.

NII skoroĭ pomoshchi im. N.V. Sklifosovskogo, Moskva

Tekaeva F.K.

Bel'gusheva M.É.

Kafedra nevrologii Rossiĭskoĭ meditsinskoĭ akademii poslediplomnogo obrazovaniia

The role of the MAO-B inhibitor razagiline in the treatment of Parkinson's disease

Authors:

Fedorova N.V., Tekaeva F.K., Bel'gusheva M.É.

More about the authors

Journal: S.S. Korsakov Journal of Neurology and Psychiatry. 2011;111(7): 30‑36

Read: 5867 times

Contact the author
Table of contents

THE ROLE OF THE MAO-B INHIBITOR RAZAGILINE IN THE TREATMENT OF PARKINSON'S DISEASE
THE ROLE OF THE MAO-B INHIBITOR RAZAGILINE IN THE TREATMENT OF PARKINSON'S DISEASE

To cite this article:

Fedorova NV, Tekaeva FK, Bel'gusheva MÉ. The role of the MAO-B inhibitor razagiline in the treatment of Parkinson's disease. S.S. Korsakov Journal of Neurology and Psychiatry. 2011;111(7):30‑36. (In Russ.)

Подписка 2026 Журнал неврологии и психиатрии им. С.С. Корсакова (S.S. Korsakov Journal of Neurology and Psychiatry)
МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Recommended articles:
Vertebroplasty for pathological vertebral fracture with osteoporosis. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(6):67-76
Effect of uric acid on the progression of Parkinson’s disease: Myth or reality?. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(7):7-14
Features of the clinical course of multiple scle­rosis as a factor in persistent disa­bility. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(7-2):39-44
Bacterial vagi­nosis: modern views. Russian Journal of Clinical Dermatology and Vene­reology. 2025;(3):261-268
Method of photodynamic action in surgical treatment of local limi­ted peri­tonitis in the expe­riment. Russian Journal of Operative Surgery and Clinical Anatomy. 2025;(2-2):77-86
Appe­ndicular dive­rticulum in acute appe­ndix. Russian Journal of Operative Surgery and Clinical Anatomy. 2025;(2-2):117-120
Pote­ntial and prospects of the astragaloside IV use for age-associated diseases prevention. Russian Journal of Preventive Medi­cine. 2025;(7):94-99
Traumatic inju­ries of the rectum and anus in childhood. Piro­gov Russian Journal of Surgery. 2025;(8):62-66
Course and outcomes of pregnancy in patients with multiple pregnancies with rhesus isoimmunization. Russian Bulletin of Obstetrician-Gynecologist. 2025;(4):59-65
Dyna­mics of permeability of the blood-brain barrier after FUS thalamotomy acco­rding to contrast-enhanced MRI. Burdenko's Journal of Neurosurgery. 2025;(4):51-60
Abstract:

The features of the new selective MAO-B inhibitor razagiline (azilect) are reviewed against the background of latest advances in the field of treatment of Parkinson's disease (PD). The authors present the results of treatment of 20 patients in the full-blown stage of disease (mean age of patients 61.4±7.0 years). One of the objectives was to study the effect of razagiline on speech disorders in PD. A battery of scales was used to assess the global efficacy of treatment and the effect of the drug on the groups of symptoms. The high symptomatic effect of the drug used as monotherapy in early stages and in the combination with levodopa drugs in the full-blown stages of disease was revealed. It has been concluded that razagiline has a neuroprotective effect and modifies the course of PD. It exerts an effect on axial symptoms of PD: reduces speech disorders, postural instability, frequency of freezing episodes, severity of pharmacological dyskinesias.

Keywords:

Parkinson's disease
treatment
MAO-B inhibitors
razagiline (azilect)

Authors:

Fedorova N.V.

NII skoroĭ pomoshchi im. N.V. Sklifosovskogo, Moskva

Tekaeva F.K.

Bel'gusheva M.É.

Kafedra nevrologii Rossiĭskoĭ meditsinskoĭ akademii poslediplomnogo obrazovaniia

Close metadata

References:

  1. Akao Y., Maruyama W., Yi H. et al.An anti-Parkinson's disease drug, N-propargyl-1-(R)-aminoindan (rasagilin), enhances expression of anti-apoptotic Bcl-2 in human dopaminergic SH-SY5Y cells. Neurosci Lett 2002; 326: 105-108.
  2. Bar Am O., Amit T., Youdim M.B.H.Contrasting neuroprotective and neurotoxic actions of respective metabolites of anti-Parkinson drag rasagiline and selegiline. Neurosc Lett 2004; 355: 169-172.
  3. Berg K., Wood-Dauphinee S., Williams J.I., Gayton D.Measuring balance in the elderly: Preliminary development of an instrument. Physiotherapy Canada 1989; 41: 304-311.
  4. Blandini F.Neuroprotection by rasagiline: a new therapeutic approach to Parkinson's disease? CNS Drug Rev 2005; 11: 183-194.
  5. Brookshire R.H.Introduction to neurogenic communication disorders (6th ed.). St. Louis, MO; Mosby 2003.
  6. Chaudhuri K.R., Healy D.G., Schapira A.H.National Institute for Clinical Excellence. Non-motor symptoms of Parkinson's disease: diagnosis and management. Lancet Neurol 2006; 5: 235-245.
  7. Chen J.J., Ly A.V.Pasagiline: A second-generation monoamine oxidase type-B inhibitor for the treatment of Parkinson's disease. Am J Health Syst Pharm 2006; 63: 915-928.
  8. Darley F.L., Aronson A.E., Brown J.R.Motor speech disorders. Philadelphia: W.B. Saunders 1975.
  9. Duffy J.R.Motor speech disorders: Substrates, differential diagnosis, and management. St. Louis, MO: Mosby 1995.
  10. Elmer L., Schwid S., Eberly S. et al.Rasagiline-associated motor improvement in PD occurs without worsening of cognitive and behavioral symptoms. J Neurol Sci 2006; 248: 78-83.
  11. Fahn S., Elton R.UPDRS program members Parkinson's Disease Rating Scale. In: Fahn S., Marsden C.D., Golstein M., Calne D.B. (ed.). Recent developments in Parkinson's disease, vol. 2. Macmillan Healthcare Information, Florham Park 1987; 153-165.
  12. Getz C.G., Poewe W., Rascol O.Mov Disordes 2005; 20: 5: 523-539.
  13. Giladi N., Shabtai H., Simon E.S. et al.Construction of freezing of gait questionnaire for patients with Parkinson's disease. Parkinsonism Relat Disord 2000; 6: 165-170.
  14. Grosset D., Taurah L., Burn D.J.J Neurol Neurosurg Psychiatry 2007; 78: 465-469.
  15. Guy W.Assessment manual for psychopharmacology. US Washington, DC: Government Printing Office 1976.
  16. Hoodin R.B., Gilbert H.R.Nasal airflows in Parkinsonian speakers. J Commun Disord 1989; 22: 169-180.
  17. Horstink M., Tolosa E., Bonucelli U. et al.Review of the therapeutic management of Parkinson's disease. Report of a joint task force of the EFNS and MDS-ES. Part II: late (complicated) Parkinson's disease. Eur J Neurol 2006; 13: 11: 1170-1185.
  18. Horstink M., Tolosa E., Bonuccelli U.et. al. Review of the therapeutic management of Parkinson's disease. Report of joint task force of the EFNS and MDS-ES. Part II: late (complicated) Parkinson's disease. Eur J Neurol 2006; 13: 1186-1202.
  19. Jacobson B., Johnson A., Grywalski C. et al.The Voice Handicap Index (VHI): Development and validation. American Journal of Speech-Language Pathology 1997; 6: 66-67.
  20. Koller W.C.Sensory symptoms in PD. Neurology 1984; 34: 957-995.
  21. Leber P.Slowing the progression of Alzheimer disease: methodological issues. Alzheimer Dis Assoc Disord 1997; 11: Suppl 5: 10-21.
  22. Lev N., Dialdetti R., Melamed E.Initiation of symptomatic therapy in Parkinson's disease: dopamine agonists vs. levodopa. J Neurol 2007; 254: Suppl 5: 19-26.
  23. Lew M.F., Hauser R.A., Hurtig H.I. et al.and the TEMPO Extension Study Group. Long-term efficacy of rasagiline in Parkinson's disease patients. Parkinsonism Relat Disord 2005; 11: Suppl 2: 129.
  24. Logemann J.A., Fisher H.B., Blonsky E. et al.Frequency and concurrence of vocal tract dysfunction in the speech of a large sample of Parkinson's individuals. Journal of Speech and Hearing Disorders 1978; 42: 47-57.
  25. Mandel S., Weinred O., Amit T. et al.Mechanism of neuroprotective action of the anti-Parkinson drug and its derivatives. Brain Res Rev 2005; 48: 379-387.
  26. Miyasaki J.M., Martin W., Suchowersky O. et al.Practice parameter: initiation of treatment for Parkinson's disease: an evidence-based review. Report of Quality Standards Subcommittee of American Academy of Neurology. Neurology 2002; 58: 11-17.
  27. Obeso J.A., Grandas F., Vaamonde J. et al.Motor complications associated with chronic levodopa therapy in Parkinson's disease. Neurology 1989; 39: Suppl 2: 11-19.
  28. Olanov C.W., Agid Y., Mizuno Y. et al.Levodopa in the treatment of Parkinson's disease: current controversies. Mov Disord 2004; 19: 997-1005.
  29. Olanow C.W., Hauser R., Jankovic J. et al.A randomized, double-blind, placebo-controlled, delayed start study to assess rasagiline as a disease modifying therapy in Parkinson's disease (the ADAGIO study): rationale, design, and baseline characteristics. Mov Disord 2008; 10: 1002.
  30. Pahwa R., Factor S.A., Lyons K.E. et al.Practice Parameter: Treatment of Parkinson's disease with motor fluctuations and dyskinesia (an evidence-based review): Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2006; 66: 983-995.
  31. Parkinson Study Group. Impact of deprenyl and tocopherol treatment on Parkinson's disease in DADATOP patients requiring levodopa. Ann Neurol 1996; 39: 37-45.
  32. Parkinson Study Group. A controlled, randomized, delayed-start study of rasagiline in early Parkinson disease. Arch Neurol 2004; 61: 561-566.
  33. Parkinson Study Group. A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson's disease and motor fluctuations: the PRESTO study. Arch Neurol 2005; 62: 241-248.
  34. Peto V., Jenkinson C., Fitzpatrik R.The development and validating of a short measure of functioning and well being for individuals with Parkinson's disease. Quality of life research 1995; 4: 241-249.
  35. Rascol O., Payoux P., Ory F. et al.Limitations of current Parkinson's disease therapy. Ann Neurol 2003; 53: Suppl 3: 515.
  36. Rascol O.Expert Opin. Pharmacother 2005; 6: 2061.
  37. Rascol O., Brooks D.J., Melamed E. et al.Rasagiline as an adjunct to levodopa in patients with Parkinson's disease and motor fluctuations (LARGO study). Lancet 2005; 365: 947-954.
  38. Samii A., Nutt J.G., Ranson B.R.Parkinson's disease. Lancet 2004; 363: 1783-1794.
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.